IDEMIA Provides Its Subscription Management to TrueMove H in Thailand to Activate the First eSIM Connected Watch in the Country
The first eSIM connected watch is now available in Thailand, thanks to a launch from TrueMove H. Based on IDEMIA subscription management, or remote SIM provisioning, the technology allows to remotely connect the embedded SIM of the smart watch to TrueMove H without the need to insert a physical SIM card. Indeed, it is a secure solution for the remote and in-life management of mobile operators’ subscription profiles in eSIM-capable wireless devices. Moreover, the offer is compliant with the latest GSMA standards ensuring interoperability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180606006166/en/
It’s the first time that the Thais can experience the full freedom of communication thanks to this innovative offer: even if users have their mobile phone at home, they can keep the same habits (make calls, send texts…). It’s a scalable solution to support TrueMove H in easily on-boarding additional eSIM-capable devices.
“The technology, which allows SIMs to be remotely programmed without the need to replace physical SIM cards, is already starting to appear in some devices, and is poised to become the new standard for mobile subscription management. We thank TrueMove H for choosing IDEMIA for this critical transformation and look forward to further developing and inspiring future innovations ”, explains Fabien Jautard, Executive Vice-President for Mobile Operators activities at IDEMIA.
“This technology revolutionizes the use of our smartphones and devices such as wearables, which can be activated and managed effortlessly, over-the-air, anytime and anywhere. Thanks to IDEMIA’s subscription management solution, we are the first mobile operator in Thailand to support IoT/M2M trends, which will enable exponential increase in connectivity and services in the near future ”, Mr. Tuantong Srivichian, Director for Retail Business, True Corporation Plc. of TrueMoveH.
OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with the ambition to provide a secure environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect, travel and vote), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
OT (Oberthur Technologies) and Safran Identity & Security (Morpho) have joined forces to form IDEMIA. With close to $3 billion in revenues and 14,000 employees around the world, IDEMIA serves clients in 180 countries.
Havas Paris PR Agency
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CA-VEEVA-SYSTEMS-INC.19.6.2019 13:21:13 CEST | Pressemeddelelse
New Survey Finds Fragmented Processes and System Silos Slowing Clinical Trials
CA-ANDERSEN-TAX19.6.2019 13:11:12 CEST | Pressemeddelelse
Andersen-navnet i fremgang i Polen
FL-VIRGIN-VOYAGES19.6.2019 13:02:11 CEST | Pressemeddelelse
Geri Horner Test Drives RockStar Suites aboard Virgin Voyages’ Scarlet Lady
CT-BEQOM19.6.2019 13:02:11 CEST | Pressemeddelelse
beqom Study Shows U.S., UK Employees Aware of Gender Wage Gaps but Not of Actions Taken by Employers or Governments to Close Them
VA-HILTON19.6.2019 12:07:06 CEST | Pressemeddelelse
Moon-Walking Mini-Breaks, 3D-Printed Room Service and Hyper-Personalised Spaces: Welcome to the Hotel of 2119
CA-INVIVOSCRIBE19.6.2019 12:02:06 CEST | Pressemeddelelse
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum